Glenmark Stock Jumps Cancer Drug Deal

  Published 6 months ago

Glenmark’s stock rises as Swiss unit secures Hengrui’s trastuzumab rezetecan licence, boosting outlook for investors.

  • Deal includes $18 million upfront and up to $1.09 billion in milestone payments for Hengrui drug rights
  • Nomura predicts the drug will drive Glenmark’s $350‑400 million innovation revenue target over the next five years alone
  • Analysts rate Glenmark “buy”; median price target 2,400 rupees, stock up 27% YTD 2025 so far

You might like these

Happiest Minds Appoints Anand Balakrishnan as CFO

Fasenra Approved for New Use in India

Deepak Fertilisers Signs LNG Deal

RBI Extends Financial Market Trading Hours

Adani Stocks Surge After SEBI Clearance

Alibaba Pictures Shares Soar 23% on Strong Earnings

Honda Q4 Earnings: Sales Up, Profits Down

News that matters the most ⚡